Nov. 19, 2013
/PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, will showcase new products at MEDICA the world's largest medical technology trade fair,
November 20 to 23
, Covalon's Chief Executive Officer said, "Since we announced the transformative license agreement with Molnlycke earlier this month, the amount of interest in our new product pipeline has spiked significantly. As a result, we have accelerated the unveiling of our FDA-cleared ColActive
Transfer wound dressing and our CovaCoat™ A.I. Anti Infective coatings. Along with our proven ColActive
Plus wound dressings and SilverCoat™ Antimicrobial Foley Catheters, our strong pipeline of new products and technologies, which includes ColActive
Transfer and CovaCoat™ A.I., positions Covalon well as a partner for wound care, urological, vascular access, surgical and orthopaedic companies and distributors."
The latest addition to the patented ColActive™ family of wound care products being showcased at MEDICA is ColActive
Transfer, Covalon's bio-degradable wound dressing that stimulates wound healing responses in difficult to heal wounds, while allowing wound fluids to pass through the dressing. ColActive
Transfer is designed to protect new-growth tissue in wounds undergoing treatment and is FDA approved for sale in
the United States
. Along with the introduction of ColActive
Transfer, Covalon anticipates entering the nearly
negative pressure dressing and kit market.
Covalon will also be unveiling its new patented CovaCoat™ A.I. Anti Infective coating technology that provides antimicrobial and anti-thrombogenic properties, without eluting antimicrobial agents from the surface of medical devices. Covalon's CovaCoat™ A.I. Anti Infective Foley Catheter significantly reduces biofilm formation on urinary catheters, the formation of which is a major source of hospital acquired infections. The use of CovaCoat™ A.I. on vascular access devices provides both anti-thrombogenic and antimicrobial characteristics without the downside of delivering potentially cytotoxic antimicrobial agents directly into the bloodstream.